Skip to main content

Table 2 Outcomes of patients who did or did not receive HES before or after cardiopulmonary bypass

From: Large volume infusions of hydroxyethyl starch during cardiothoracic surgery may be associated with postoperative kidney injury: propensity-matched analysis

 

HES (n = 536)

Control (n = 1440)

p value

AKI incidents

151 (28.2%)

374 (26.0%)

0.33

AKI stage

 1

93 (17.4%)

229 (15.9%)

 

 2

20 (3.7%)

53 (3.7%)

 

 3

38 (7.1%)

92 (6.4%)

 

Peak serum creatinine (mg/dL)

0.96 (0.77–1.27)

0.93 (0.71–1.35)

0.28

Need for RRT

30 (5.6%)

74 (5.1%)

0.73

ICU length of stay (days)

3 (3–5)

3 (3–4)

0.0079

28-day hospital free days (days)

11 (4–14)

12 (6–15)

0.060

Hospital mortality

22 (4.1%)

38 (2.6%)

0.10

  1. Data are expressed as medians with 25th to 75th percentiles or percentages
  2. HES hydroxyethyl starch, AKI acute kidney injury, RRT renal replacement therapy, ICU intensive care unit